A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study is for Japanese participants with congenital protein C deficiency. The main aim of
this study is to check how much TAK-662 stays in their blood over time. This will help the
study sponsor (Takeda) to work out the best dose to give patients in the future.
Participants will receive 1 single infusion of TAK-662.
They will stay at the clinic until 3 days after the infusion. Then, participants will return
to their clinic 7days after the infusion to check side effect from the study treatment.